Especially, isocitrate dehydrogenase (IDH) mutations [5, 6] and fibroblast growth factor receptor 2 (FGFR2) fusion genes [7–12] in ICC have been identified as important driver alterations and are promising therapeutic targets. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.